VESTAL — Binghamton University and Cornell University have signed an agreement that will allow Cornell students in the plant-sciences major to transfer into Binghamton’s doctor of pharmacy (PharmD) program after three years of undergraduate study.
The Binghamton University School of Pharmacy and Pharmaceutical Sciences signed the articulation agreement with the Cornell University College of Agriculture and Life Sciences, Binghamton said in a July 10 news release.
Referred to as a “3 + 4 program,” it will allow qualified Cornell students to complete their bachelor’s degree in plant sciences through coursework taken in their first professional year at Binghamton.
“We’re thrilled to have developed this articulation agreement with Cornell University’s College of Agriculture and Life Sciences,” Gloria Meredith, founding dean of the School of Pharmacy and Pharmaceutical Sciences, said. “This agreement builds on the many relationships we are developing with Cornell, such as with Veterinary Medicine in Lyme disease research, but importantly, it provides an opportunity for qualified Cornell students who are studying the plant sciences to seamlessly enter our PharmD program, enabling them to become pharmacists who will provide exceptional, patient-centered healthcare.”
Students must have successfully completed the required prerequisite credits from Cornell with a specified grade point average (GPA). Interested students must carry a minimum cumulative GPA of 3.0. The Pharmacy College Admissions Test (PCAT) will be waived for students who maintain the 3.0 GPA minimums, Binghamton said. Students must also apply no later than Jan. 1 of the year they plan to enroll at Binghamton.
“This partnership supports the crucial need for innovative professionals in today’s pharmacy environment,” Kathryn Boor, dean of the Cornell University College of Agriculture and Life Sciences, said in the Binghamton news release. “By connecting world-class scientific learning in the plant sciences with pharmaceutical sciences, we are preparing students to serve their communities by providing evidence-based pharmaceutical care and innovative research.”